

VALIDATION OF THE SPECTROPHOTOMETRIC METHOD FOR THE DETERMINATION OF FAVIPIRAVIR FOR THE QUALITY CONTROL OF TABLETS

YU.V. SCRYPNETS, I.I. CHEBOTARSKA, D.I. ALEKSANDROVA, S.N. KASHUTSKYY, A.V. YEGOROVA

References:

1. WHO. Novel coronavirus – Thailand (ex-China). Geneva: World Health Organization, Jan 14, 2020. <https://www.who.int/csr/don/14-january-2020-novel-coronavirus-thailand/en/> (accessed Jan 23, 2020).
2. Shiraki, K.; Daikoku, T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. *Pharmacol. Ther.* 2020, 209, 107512. <https://doi.org/10.1016/j.pharmthera.2020.107512>.
3. Martinez, M.A. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. *Antimicrob. Agents Chemother.* 2020, 21, 64–69. e00399-20. <https://doi.org/10.1128/AAC.00399-20>.
4. Scrypynets, Yu.V.; Fedosenko, G.O.; Maltsev, G.V.; Chebotarska, I.I.; Aleksandrova, D.I.; Kashutskyy, S.N.; Yegorova, A.V. Development and validation of new methods for quality control of the antiviral substance favipiravir. *Methods and objects of chemical analysis.* 2023, 18, (2), 70–80. <https://doi.org/10.17721/moca.2023.70-80>.
5. Sharaf, Y.A.; Abd El-Fattah, M.H.; El-Sayed, H.M. et al. Spectrophotometric determination of favipiravir in presence of its acid hydrolysis product. *BMC Chem.* 2023, 17, 129. <https://doi.org/10.1186/s13065-023-01046-6>.
6. Ramzy, S.; Abdelazim, A.H.; Osman, A.; Hasan, M.A. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma. *Spectrochim. Acta, Part A.* 2022, 281, 121625. <https://doi.org/10.1016/j.saa.2022.121625>.
7. Galal, A.; Ahmed, Y.M.; Ahmed, M.H.; Atta, N.F. Electrochemistry and determination of an antiviral drug at ionic liquids crystals-carbon nanotubes modified glassy carbon electrode. *J. Electrochem. Soc.* 2021, 168, (11), 116512. <https://doi.org/10.1149/1945-7111/ac39d6>.
8. Taskin, D. Development and validation of a rapid HPLC-DAD method for determination of favipiravir in pharmaceutical formulation. *Clin. Exp. Health Sci.* 2022, 12, 648–652. <https://doi.org/10.33808/clinexphealthsci.992869>.
9. Sabriye, A.M.; Metin, B. Favipiravir Determination in Pharmaceutical Formulation via HPLC Chromatographic Approach. *Iran. J. Chem. Chem. Eng.* 2023, 42, (4), 1183–1191. <https://doi.org/10.30492/ijcce.2022.547653.5147>.
10. Bulduk, İ. Comparison of HPLC and UV Spectrophotometric Methods for Quantification of Favipiravir in Pharmaceutical Formulations. *Iran. J. Pharm. Res.* 2021, 20, (3), 57–65. <https://doi.org/10.22037/ijpr.2020.114199.14725>.
11. IMWP, Monographs on Favipiravir and on Favipiravir tablets, 2021 <https://www.who.int/publications/m/item/imwp-monographs-on-favipiravir-and-on-favipiravir-tablets>.
12. Jyothi, B.J.; Kavya, R.V. Ultraviolet spectrophotometric method development for estimation of new antiviral repurposing drug favipiravir. *Asian J. Pharm. Clin. Res.* 2021, 14(7), 67–69. <https://doi.org/10.22159/ajpcr.2021.v14i7.41966>.
13. Derzhavna Farmakopeia Ukrainy: v 3 t. / Derzhavne pidpriemstvo «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv». 2-e vyd. Dopovnennia 4. Kharkiv: Derzhavne pidpriemstvo «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv», 2020, 123–236.